Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Zscaler Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.8 (market cap $4.59B), while Zscaler Inc trades at $234 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 7.7× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Zscaler Inc for 41 Days on average.
| DFTX | ZS | |
|---|---|---|
Market Cap | $4.59B | $35.35B |
Volume | 2,103,937 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $48.45 | $336.27 |
52-Week Low | $10.68 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $3.55B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zscaler (ZS) trades at $230.23, up 7.81% in the last 24 hours, with a bullish technical signal from moving averages. The company reported strong revenue growth, reaching $2.67 billion in 2025, and has beaten EPS estimates for three consecutive quarters. However, it remains unprofitable with a net income margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day on October 6, 2026.
The outlook is mixed: robust revenue growth and AI-driven bookings offer upside, but profitability concerns and high valuation multiples pose risks. Analyst consensus is bullish with a $222.83 price target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
